We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: multiple myeloma
MedXY News
EnglishTag

multiple myeloma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients
Allergy & ImmunologyCAR T-cell therapyClonal hematopoiesis

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients

By MedXY|Oct 5, 2025

Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for p

Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study
Hematology-Oncologyimmunocytokine
multiple myeloma

Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study

By MedXY|Oct 5, 2025

This phase 2 trial evaluated modakafusp alfa, a novel immunocytokine targeting CD38+ cells, in heavily pretreated relapsed/refractory multiple myeloma, showing promising efficacy and manageable toxicity despite early termination.

Advancements in Long-Term Outcomes for Multiple Myeloma: Insights from Early Total Therapy Protocols
Clinical Updateslong-term survivalmultiple myeloma

Advancements in Long-Term Outcomes for Multiple Myeloma: Insights from Early Total Therapy Protocols

By MedXY|Aug 23, 2025

A secondary analysis of three total therapy clinical trials reveals significant long-term survival improvements in multiple myeloma patients with modern combinational and stem cell transplant approaches incorporating immunomodulatory and pr

Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial
Clinical Updatesclinical trialisatuximab

Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial

By MedXY|Oct 1, 2025

The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA
Clinical Updatesdaratumumabminimal residual disease

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

By MedXY|Oct 1, 2025

Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.

Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial
Clinical Updatesmultiple myelomaoverall survival

Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial

By MedXY|Oct 1, 2025

Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.

Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial
Clinical Updatescarfilzomibdaratumumab

Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial

By MedXY|Oct 1, 2025

KRd and D-KRd regimens outperform VMP 9-Rd 9 in achieving deeper responses in older, fit, transplant-ineligible multiple myeloma patients, but toxicity remains a concern, particularly with quadruplet therapy.

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial
Clinical UpdatescarfilzomibDexamethasone

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY|Oct 1, 2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights
Clinical Updatesbelantamab mafodotinmultiple myeloma

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights

By MedXY|Oct 1, 2025

The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients
Clinical UpdatesCAR-TCAR-T Therapy

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

By MedXY|Sep 30, 2025

A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial
Clinical Updatesautologous stem-cell transplantationmeasurable residual disease

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial

By MedXY|Sep 30, 2025

MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.

Prev
3 / 3
123
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities